Novel ligands and modulators of triggering receptor expressed on myeloid cells receptor family: 2015-2020 updates. (3rd June 2021)

• Record Type: Journal Article
• Authors: Singh, Harbinder; Rai, Vikrant; Nooti, Sunil K.; Agrawal, Devendra K.
• Is Part Of: Expert opinion on therapeutic patents. Volume 31:Number 6(2021)
• Page Start: 549
• Page End: 561
• Publication Date: 2021-06-03
• Subjects: ADAMs -- arthritis -- atherosclerosis -- dap12 -- eCIRP -- extracellular actin -- hmgb-1 -- hsp70 -- infectious diseases -- pglyrp1 -- sepsis -- trem-1 -- trem-2 -- trem-like transcripts -- TREM modulators; Drugs -- Patents -- Periodicals; 615.10272
• DOI: 10.1080/13543776.2021.1883587
• Languages: English
• ISSNs: 1354-3776

Abstract

ABSTRACT: Introduction : Triggering receptors expressed on myeloid cells (TREMs) are inflammatory amplifiers with defined pathophysiological role in various infectious diseases, acute and chronic aseptic inflammations, and a variety of cancers, depicting TREMs as prominent therapeutic targets. Areas covered : Herein, updates from 2015 to 2020 are discussed to divulge the TREM ligands, as well as their peptide blockers, claimed to modulate their expression. The article also presents different strategies employed during the last five years to block interactions between TREMs and their ligands to treat various disease conditions by modulating their expression and activity. Expert opinion : There has been significant progress in the discovery of novel ligands and modulators of TREMs in the last five years that mainly revolved around the function of TREM molecules. A few peptides showed encouraging results to modulate the expression and activity of TREMs in preclinical studies, and these peptides are currently under clinical investigation. Based on the findings so far in several careful studies, we expect novel therapeutics in the near future which could have the ability to treat various disease conditions associated with TREM expression.